Developing a cost-effective method for producing therapeutic proteins.
Official title: A new platform for inexpensive and scalable recombinant protein and growth factor production to support cell culture applications in therapeutics.
Funded at Opera Bioscience, INC. · NIH-11266102 · Data updated 2026-11-12
This study is working on a new way to produce important proteins that help with treatments like CAR-T cell therapy, using a special bacteria to make the process faster and cheaper, so more people can benefit from these therapies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Opera Bioscience, INC. NIH-funded |
| Lab location | 1 site (Evanston, UNITED STATES) |
| Project start | September 20, 2024 |
| Project end | September 19, 2025 |
| Funding year | 2025 |
| Award (this year) | $47,879 |
| NIH project number | 3R43GM146560-01A1S1 |
| Project ID | NIH-11266102 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include patients who may require CAR-T cell therapies or other treatments that rely on recombinant proteins.
✕Less likely to help
Patients who do not require therapies involving recombinant proteins or growth factors may not benefit from this research.
What this research studies
This research focuses on creating a new platform that utilizes a bacterial system to produce growth factors and recombinant proteins more efficiently and at a lower cost. By leveraging the type III secretion system of Salmonella enterica, the project aims to streamline the production process, making it easier to generate the proteins needed for various therapeutic applications, including advanced cell therapies like CAR-T cells. This innovative approach could significantly reduce the manufacturing costs associated with these critical biological products, thereby increasing their accessibility for research and treatment.
Why it matters
Potential benefit: If successful, this research could lead to more affordable and accessible therapeutic proteins, enhancing treatment options for patients requiring advanced therapies.
How similar studies have gone: Other research has shown promise in using bacterial systems for protein production, indicating that this approach could be effective.
Where this research is happening
-
Opera Bioscience, INC.
Evanston, United States Active
Researchers
- Principal investigator: Liang, Julie Ming — Opera Bioscience, INC.
- Study coordinator: Liang, Julie Ming
Related research
Other NIH-funded projects on the same topics.
-
Developing a cost-effective method for producing proteins used in therapies.
This study is working on a new way to make important proteins for treatments like CAR-T cell therapy using a special bacteria, which could help make these therapies cheaper and easier for patients to get.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.